Product Code: GVR-3-68038-699-8
Helicobacter Pylori Diagnostics Market Growth & Trends:
The global helicobacter pylori diagnostics market size is anticipated to reach USD 757.84 million by 2030, according to a new report by Grand View Research. It is expected to expand at a CAGR of 4.5% over the forecast period. Increasing demand for personalized antibiotic therapy coupled with improved cost-effectiveness Helicobacter pylori (H. pylori) infection diagnosis is projected to drive the growth.
Easy accessibility and affordability of antibiotics along with short treatment durations will boost the adoption of antibiotics as well as the demand for pre and post monitoring tests. Furthermore, factors such as rising incidence of H. pylori infections, need for early diagnosis, and rapid technological advancements in diagnostic techniques will propel the market growth. However, rising pressure of maintaining economic pricing due to the extremely competitive environment may hinder the growth of the Helicobacter pylori diagnostics market.
H. pylori is an aerobic gram-negative bacteria generally found in the stomach. Although advantageous for balancing the stomach ecology, it can cause infection to the inner stomach lining. The bacteria can act as one of the causative agents for stomach cancer, duodenal ulcers, gastritis and gastric ulcers, and infection to the small intestine, among other conditions. This has led to an increase in the demand for Helicobacter pylori diagnostics that enable early detection of H. pylori infection. Patients are subject to an antibiotic therapy for 10 to 14 days, in case of positive diagnosis of ulcers caused by this bacteria. Treatment for H. pylori could include a combination of antibiotics such as metronidazole, amoxicillin, clarithromycin, tetracycline, or with a proton pump inhibitor, ranitidine bismuth citrate, and bismuth subsalicylate.
The immunoassay technology segment held the largest market share in 2018 and is expected to register the fastest CAGR over the forecast period. In terms of end user, the hospital segment held the largest market share in 2018, while diagnostic laboratories is anticipated to expand at the fastest CAGR in the forthcoming years. In terms of region, North America led the global market for Helicobacter pylori diagnostics. Asia Pacific, on the other hand, is expected to witness the fastest CAGR from 2019 to 2026.
Helicobacter Pylori Diagnostics Market Report Highlights:
- Immunoassays technology held the largest market share in 2022 and is expected to witness the fastest CAGR over the forecast period
- Among end user, hospital segment held the largest market share in 2022, while the diagnostics laboratories segment is expected to demonstrate the fastest CAGR from 2023 to 2030
- Latin America is anticipated to grow at the fastest CAGR of 6.4% in the forecast period owing to the rising importance to the healthcare sector, increasing infectious diseases prevalence, and awareness.
- Key players operating in the Helicobacter pylori diagnostics market include Thermo Fisher Scientific, Biohit, Meridian Bioscience, Bio-Rad Laboratories, F. Hoffmann-La Roche, Alpha Laboratories, Quest Diagnostics, Coris BioConcept, Certest Biotec, and Epitope Diagnostics
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Technology
- 1.1.3. End-user
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Technology outlook
- 2.2.3. End-user outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Helicobacter Pylori Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Helicobacter Pylori Diagnostics Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Helicobacter Pylori Diagnostics Market: Type Estimates & Trend Analysis
- 4.1. Helicobacter Pylori Diagnostics Market: Key Takeaways
- 4.2. Helicobacter Pylori Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Instruments
- 4.3.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Reagents
- 4.4.1. Reagents market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Services
- 4.5.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Helicobacter Pylori Diagnostics Market: Technology Estimates & Trend Analysis
- 5.1. Helicobacter Pylori Diagnostics Market: Key Takeaways
- 5.2. Helicobacter Pylori Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Immunoassays
- 5.3.1. Immunoassays market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. POC
- 5.4.1. POC market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Molecular Diagnostics
- 5.5.1. Molecular diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Helicobacter Pylori Diagnostics: End-user Estimates & Trend Analysis
- 6.1. Helicobacter Pylori Diagnostics Market: Key Takeaways
- 6.2. Helicobacter Pylori Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Hospitals
- 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Diagnostics Laboratories
- 6.4.1. Diagnostics laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Clinics
- 6.5.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Helicobacter Pylori Diagnostics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Helicobacter Pylori Diagnostics Market by Region: Key Takeaway
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Sweden
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Norway
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. Saudi Arabia
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Thermo Fisher Scientific
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Biohit Oyj
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Quest Diagnostics Incorporated
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Meridian Bioscience
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Bio-Rad Laboratories
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Alpha Laboratories Ltd
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. F. Hoffmann-La Roche Ltd
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Coris BioConcept
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Certest Biotec
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Epitope Diagnostics, Inc.
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives